SCHEMBL1133635

SCHEMBL1133635

O=C(O)CN1C=CC=Cc2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 11/20 0.41
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
SCN4A P35499 1/20 0.40
SCN5A Q14524 1/20 0.40
SCN9A Q15858 1/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
P2RX1 P51575 5/20 0.38
P2RX3 P56373 5/20 0.38
P2RX7 Q99572 2/20 0.37
PTBP1 P26599 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
APEX1 P27695 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MTNR1A P48039 2/20 0.36
MTNR1B P49286 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29383470 0.98 P2RX4 (0.40) P2RX4LMNATSHRMAPK1SCN4A
Hydrochloric Acid SCHEMBL3122652 0.98 P2RX4 (0.40) P2RX4LMNATSHRMAPK1SCN4A
SCHEMBL27498070 0.78 KMT2A (0.41) P2RX4LMNASCN9AP2RX1P2RX3
SCHEMBL27769491 0.78 SLC6A1 (0.37) P2RX4LMNATSHRMAPK1SCN4A
SCHEMBL9030241 0.76 P2RX4 (0.37) P2RX4LMNAMAPK1P2RX1P2RX3
SCHEMBL9030962 0.75 MAPT (0.38) P2RX4LMNATSHRMAPK1SCN4A
SCHEMBL20987115 0.74 MAPK1 (0.35) P2RX4LMNATSHRMAPK1SCN4A
SCHEMBL3687782 0.74 P2RX4 (0.44) P2RX4LMNATSHRMAPK1SCN4A
SCHEMBL7333680 0.72 P2RX4 (0.40) P2RX4LMNATSHRMAPK1SCN4A
SCHEMBL11534924 0.71 KMT2A (0.41) LMNATSHRMAPK1SCN4ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2034967-B1 ORAL PHARMACEUTICAL COMPOSITION OF A POORLY WATER-SOLUBLE ACTIVE SUBSTANCE ABBOTT HEALTHCARE PRODUCTS BV (NL) 2011-05-18 EP claimed
EP-1848439-B1 ORAL IMMEDIATE RELEASE FORMULATION OF A POORLY WATERSOLUBLE ACTIVE SUBSTANCE SOLVAY PHARM BV (NL) 2010-03-10 EP claimed
US-20070292503-A1 ORAL PHARMACEUTICAL COMPOSITION OF POORLY WATER-SOLUBLE ACTIVE SUBSTANCE SOLVAY PHARMACEUTICALS B.V. (NL) 2007-12-20 US claimed
CN-101087612-A Oral immediate release formulation of a poorly watersoluble active substance SOLVAY PHARM BV (NL) 2007-12-12 CN claimed
EP-1848439-A1 ORAL IMMEDIATE RELEASE FORMULATION OF A POORLY WATERSOLUBLE ACTIVE SUBSTANCE Solvay Pharmaceuticals B.V. (NL) 2007-10-31 EP claimed
US-7273860-B2 Method and pharmaceutical compositions for treating or inhibiting renal dysfunctions, diseases or disorders, particularly in diabetic patients SOLVAY PHARMACEUTICALS GMBH (DE) 2007-09-25 US claimed
WO-2007102171-A2 NOVEL SALTS OF 1H-1-BENZAZEPINE-1-ACETIC ACID, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION PANACEA BIOTEC LTD (IN) 2007-09-13 WO claimed
EP-1476196-B1 ORAL SOLID SOLUTION FORMULATION OF A POORLY WATER-SOLUBLE ACTIVE SUBSTANCE SOLVAY PHARM BV (NL) 2006-11-22 EP claimed
US-20060159748-A1 Oral immediate release formulation of a poorly water-soluble active substance PANACEA BIOTEC LTD. (IN) 2006-07-20 US claimed
WO-2006067150-A1 ORAL IMMEDIATE RELEASE FORMULATION OF A POORLY WATERSOLUBLE ACTIVE SUBSTANCE SOLVAY PHARMACEUTICALS B.V. (NL) 2006-06-29 WO claimed
JP-10101565-A None JP disclosed
CN-111808011-B High penetration composition and its application 泰飞尔生物医药(苏州)有限公司 2024-02-27 CN disclosed
US-20230233516-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS TECHFIELDS PHARMA CO., LTD (CN) 2023-07-27 US disclosed
US-11541029-B2 High penetration compositions and their applications TECHFIELDS PHARMA CO., LTD. (CN) 2023-01-03 US disclosed
CN-108676076-A The method for preparing guanosine cyclic mono-phosphate agonist 辛纳吉制药公司 2018-10-19 CN disclosed
WO-2000048601-A1 MEDICAMENT FOR TREATING HYPERTENSION SOLVAY PHARMACEUTICALS GMBH (DE) 2000-08-24 WO disclosed
US-5783573-A Pharmaceuticals which promote gastrointestinal blood circulation SOLVAY PHARMACEUTICALS GMBH (DE) 1998-07-21 US disclosed
JP-H10101565-A EMPLOYMENT OF BENZAZEPINE-N-ACETIC ACID DERIVATIVE FOR PRODUCING MEDICINAL PREPARATION FOR TREATING AND PREVENTING GASTROINTESTINAL HEMATOGENOUS INJURY SOLVAY PHARMACEUT GMBH 1998-04-21 JP disclosed
EP-0830863-A1 Drugs for increasing gastrointestinal blood supply Solvay Pharmaceuticals GmbH (DE) 1998-03-25 EP disclosed
EP-0292923-A2 Piperidine compounds and pharmaceutical uses thereof Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1988-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060159748-A1 Oral immediate release formulation of a poorly water-soluble active substance SUCNR1, SI, TREH P2RX4 2357/4885LMNA 1337/4885TSHR 2926/4885
US-20070292503-A1 ORAL PHARMACEUTICAL COMPOSITION OF POORLY WATER-SOLUBLE ACTIVE SUBSTANCE KCNN1, CACNA2D1, KCNN2 P2RX4 2402/4885LMNA 1598/4885TSHR 4127/4885
US-11541029-B2 High penetration compositions and their applications SLC19A1, HIRA, SLC43A1 P2RX4 3191/4885LMNA 1775/4885TSHR 4827/4885
US-20230233516-A1 HIGH PENETRATION COMPOSITIONS AND THEIR APPLICATIONS SLC5A7, SLC19A1, SLC43A1 P2RX4 1657/4885LMNA 2635/4885TSHR 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.